Transabdominal US-guided (UGET) vs. Modified Transvaginal US-guided (mTVET) Embryo Transfer in Human IVF

NCT ID: NCT02526472

Last Updated: 2015-08-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1648 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One thousand, six hundred forty-eight IVF patients undergoing ET with fresh embryos, randomized to receive mTVET (n=828) or UGET (n=820). The transfer in uteri of 1-2 embryos on day 2-3 of culture was performed using a soft catheter either under trans-abdominal US guidance (UGET group) or after measurement of uterine cavity by transvaginal US and calculation of the discharge site (mTVET). Mai outcome measures was the clinical pregnancy rate (CPR), secondary outcomes were the implantation rate (IR), and the patient's discomfort during ET procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients undergoing IVF and ending the cycle with the transfer of fresh embryos at investigators' IVF Unit in a 3-years period (n=1824) were proposed to join the study. One hundred forty-six eligible patients refused to sign the consent and were excluded. Overall, 1678 patients accepted to participate in the study and the day of ET were randomized with a 1:1 ratio into two groups using a computer-generated unrestricted randomization: 866 patients were scheduled to undergo UGET, whereas 872 patients were scheduled to receive mTVET. During ET, 90 patients (44 in mTVET group and 46 in UGET group) required to change the catheter for cervical stenosis and consequently were excluded from the analysis. Finally, data of 1648 patients (828 in mTVET group vs. 820 in UGET group) were analyzed.

All cases included in the final analysis were transfers performed on day 2-3 with fresh embryos deriving from autologous IVF. Transfers with frozen embryos and cases in which blastocyst transfer was scheduled were not selected as eligible; donor IVF cycles were not legal in Italy at the time of the study. According to the investigators' usual clinical practice, no mock or trial embryo transfer was performed.

The patient was placed in the lithotomy position, and the cervix was exposed using a speculum. Then, the cervix was gently cleaned using saline solution and the cervical mucus leaking out from the cervical os was removed using a wet gauze.

In order to avoid any bias linked to the operator's experience and skill, all ETs included in the study were performed by three experienced doctors that used the same soft catheter (Sydney®Cook, Melbourne, Australia) loaded by experienced biologists with a constant amount (20 μl) of culture medium. The Sydney catheter was used for all randomized patients, but if cervical stenosis was encountered and ET was difficult, the catheter was changed shifting to a stiffer one. Neither a tenaculum, nor suture points placed on the cervix to pull it were used. All cases with change of the catheter were excluded from the final analysis.

A gentle and slow insertion of the stiffer outer sheath of the catheter was performed, and after inserting the softer inner cannula carrying the embryos, they were gently discharged and the catheter was retracted very slowly. The catheter was immediately and carefully checked under a microscope and if embryos were retained, they were re-harvested to immediately repeat the transfer procedure. These cases were included in the final analysis. The presence of blood inside the cannula was registered. The overall time needed to perform ET (defined as the time elapsed since the loaded catheter was handed by the physician to the time it was returned to the biologist after embryo discharge) was measured and registered.

When UGET was used, a second physician assisted the ET performing trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface, which was observed to be the best replacement site according to a previous research by the investigators' group (6).

When mTVET was scheduled, the physician performed a transvaginal US scan using a 6.5 mega-hertz (MHz) transvaginal probe just before ET, visualized the uterus in a sagittal plane, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, the probe was taken away from the vagina, a speculum was inserted and ET was performed inserting the inner cannula of the Sydney catheter (that has length markers on it) in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.

Immediately after either UGET or mTVET, the position of the echogenic spot(s) inside the uterus, corresponding to air bubbles loaded with the embryos, was checked by trans-vaginal US, and after waiting approximately 30 seconds its distance (or the distance of a virtual point in the middle of two spots) from the fundal endometrial surface was measured, obtaining the final position of embryo replacement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

transabdominal US guidance (UGET)

ET under transabdominal US guidance (UGET)

Group Type EXPERIMENTAL

ET under transabdominal US guidance (UGET)

Intervention Type PROCEDURE

When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface

TV-US ET guidance (mTVET)

ET after transvaginal US uterine measurement (mTVET)

Group Type EXPERIMENTAL

ET after transvaginal US uterine measurement (mTVET)

Intervention Type PROCEDURE

When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ET under transabdominal US guidance (UGET)

When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface

Intervention Type PROCEDURE

ET after transvaginal US uterine measurement (mTVET)

When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients undergoing autologous IVF
* ending IVF cycle with the transfer of fresh embryos
* treated at the investigators'r IVF Unit between Jan 2012 to Dec 2014

Exclusion Criteria

* patients undergoing donor IVF
* ending IVF cycle without embryo transfer
* transferring frozen-thawed embryos
* treated elsewhere
Minimum Eligible Age

18 Years

Maximum Eligible Age

43 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Turin, Italy

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alberto Revelli

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alberto Revelli, Prof.

Role: PRINCIPAL_INVESTIGATOR

Dept. Surgical Sciences, Sant'Anna Hospital, University of Torino, Italy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Physiopathology of Reproduction and IVF Unit, S. Anna Hospital

Torino, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FDR-2-2015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.